vs
Forestar Group Inc.（FOR）与PHIBRO ANIMAL HEALTH CORP（PAHC）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是Forestar Group Inc.的1.4倍（$373.9M vs $273.0M），PHIBRO ANIMAL HEALTH CORP净利率更高（7.3% vs 5.6%，领先1.7%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 9.0%），PHIBRO ANIMAL HEALTH CORP自由现金流更多（$8.3M vs $-157.1M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs -9.6%）
福雷斯特集团是一家住宅地块开发企业，总部位于得克萨斯州阿灵顿，业务覆盖美国21个州的51个市场。截至2020年12月31日的12个月内，该公司交付了11518块住宅地块，目前在纽约证券交易所上市，自2002年起就是美国规模最大的住宅建筑商D.R. Horton的控股子公司。
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
FOR vs PAHC — 直观对比
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $273.0M | $373.9M |
| 净利润 | $15.4M | $27.5M |
| 毛利率 | 20.1% | 35.5% |
| 营业利润率 | 7.6% | 13.5% |
| 净利率 | 5.6% | 7.3% |
| 营收同比 | 9.0% | 20.9% |
| 净利润同比 | -6.7% | 762.1% |
| 每股收益（稀释后） | $0.30 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $273.0M | $373.9M | ||
| Q3 25 | $670.5M | $363.9M | ||
| Q2 25 | $390.5M | $378.7M | ||
| Q1 25 | $351.0M | $347.8M | ||
| Q4 24 | $250.4M | $309.3M | ||
| Q3 24 | $551.3M | $260.4M | ||
| Q2 24 | $318.4M | $273.2M | ||
| Q1 24 | $333.8M | $263.2M |
| Q4 25 | $15.4M | $27.5M | ||
| Q3 25 | $86.9M | $26.5M | ||
| Q2 25 | $32.9M | $17.2M | ||
| Q1 25 | $31.6M | $20.9M | ||
| Q4 24 | $16.5M | $3.2M | ||
| Q3 24 | $81.5M | $7.0M | ||
| Q2 24 | $38.7M | $752.0K | ||
| Q1 24 | $45.0M | $8.4M |
| Q4 25 | 20.1% | 35.5% | ||
| Q3 25 | 22.3% | 32.9% | ||
| Q2 25 | 20.4% | 29.0% | ||
| Q1 25 | 22.6% | 30.1% | ||
| Q4 24 | 22.0% | 32.9% | ||
| Q3 24 | 23.9% | 32.1% | ||
| Q2 24 | 22.5% | 31.9% | ||
| Q1 24 | 24.9% | 30.2% |
| Q4 25 | 7.6% | 13.5% | ||
| Q3 25 | 16.9% | 14.1% | ||
| Q2 25 | 11.2% | 8.9% | ||
| Q1 25 | 11.6% | 9.6% | ||
| Q4 24 | 8.7% | 8.3% | ||
| Q3 24 | 19.7% | 6.8% | ||
| Q2 24 | 16.2% | 6.7% | ||
| Q1 24 | 17.6% | 7.6% |
| Q4 25 | 5.6% | 7.3% | ||
| Q3 25 | 13.0% | 7.3% | ||
| Q2 25 | 8.4% | 4.5% | ||
| Q1 25 | 9.0% | 6.0% | ||
| Q4 24 | 6.6% | 1.0% | ||
| Q3 24 | 14.8% | 2.7% | ||
| Q2 24 | 12.2% | 0.3% | ||
| Q1 24 | 13.5% | 3.2% |
| Q4 25 | $0.30 | $0.67 | ||
| Q3 25 | $1.70 | $0.65 | ||
| Q2 25 | $0.65 | $0.43 | ||
| Q1 25 | $0.62 | $0.51 | ||
| Q4 24 | $0.32 | $0.08 | ||
| Q3 24 | $1.59 | $0.17 | ||
| Q2 24 | $0.76 | $0.02 | ||
| Q1 24 | $0.89 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $211.7M | $74.5M |
| 总债务越低越好 | $793.2M | $624.2M |
| 股东权益账面价值 | $1.8B | $332.4M |
| 总资产 | $3.2B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.44× | 1.88× |
8季度趋势，按日历期对齐
| Q4 25 | $211.7M | $74.5M | ||
| Q3 25 | $379.2M | $85.3M | ||
| Q2 25 | $189.2M | $77.0M | ||
| Q1 25 | $174.3M | $70.4M | ||
| Q4 24 | $132.0M | $67.1M | ||
| Q3 24 | $481.2M | $89.8M | ||
| Q2 24 | $359.2M | $114.6M | ||
| Q1 24 | $416.2M | $98.7M |
| Q4 25 | $793.2M | $624.2M | ||
| Q3 25 | $802.7M | $628.0M | ||
| Q2 25 | $872.8M | $631.7M | ||
| Q1 25 | $872.5M | $635.4M | ||
| Q4 24 | $806.8M | $639.1M | ||
| Q3 24 | $706.4M | $295.2M | ||
| Q2 24 | $706.1M | $312.1M | ||
| Q1 24 | $705.7M | — |
| Q4 25 | $1.8B | $332.4M | ||
| Q3 25 | $1.8B | $311.7M | ||
| Q2 25 | $1.7B | $285.7M | ||
| Q1 25 | $1.6B | $266.0M | ||
| Q4 24 | $1.6B | $246.8M | ||
| Q3 24 | $1.6B | $258.5M | ||
| Q2 24 | $1.5B | $256.6M | ||
| Q1 24 | $1.5B | $270.1M |
| Q4 25 | $3.2B | $1.4B | ||
| Q3 25 | $3.1B | $1.4B | ||
| Q2 25 | $3.1B | $1.4B | ||
| Q1 25 | $3.0B | $1.3B | ||
| Q4 24 | $3.0B | $1.3B | ||
| Q3 24 | $2.8B | $966.3M | ||
| Q2 24 | $2.7B | $982.2M | ||
| Q1 24 | $2.6B | $979.0M |
| Q4 25 | 0.44× | 1.88× | ||
| Q3 25 | 0.45× | 2.01× | ||
| Q2 25 | 0.52× | 2.21× | ||
| Q1 25 | 0.53× | 2.39× | ||
| Q4 24 | 0.50× | 2.59× | ||
| Q3 24 | 0.44× | 1.14× | ||
| Q2 24 | 0.47× | 1.22× | ||
| Q1 24 | 0.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-157.0M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $-157.1M | $8.3M |
| 自由现金流率自由现金流/营收 | -57.5% | 2.2% |
| 资本支出强度资本支出/营收 | 0.0% | 3.0% |
| 现金转化率经营现金流/净利润 | -10.19× | 0.70× |
| 过去12个月自由现金流最近4个季度 | $93.0M | $47.3M |
8季度趋势，按日历期对齐
| Q4 25 | $-157.0M | $19.4M | ||
| Q3 25 | $256.3M | $9.3M | ||
| Q2 25 | $15.8M | $21.3M | ||
| Q1 25 | $-19.8M | $43.2M | ||
| Q4 24 | $-450.0M | $3.1M | ||
| Q3 24 | $119.2M | $12.6M | ||
| Q2 24 | $-61.7M | $28.4M | ||
| Q1 24 | $-59.2M | $11.4M |
| Q4 25 | $-157.1M | $8.3M | ||
| Q3 25 | $255.6M | $-4.5M | ||
| Q2 25 | $15.0M | $8.1M | ||
| Q1 25 | $-20.5M | $35.4M | ||
| Q4 24 | — | $-4.7M | ||
| Q3 24 | $118.4M | $3.0M | ||
| Q2 24 | $-62.3M | $15.4M | ||
| Q1 24 | $-59.8M | $1.7M |
| Q4 25 | -57.5% | 2.2% | ||
| Q3 25 | 38.1% | -1.2% | ||
| Q2 25 | 3.8% | 2.1% | ||
| Q1 25 | -5.8% | 10.2% | ||
| Q4 24 | — | -1.5% | ||
| Q3 24 | 21.5% | 1.2% | ||
| Q2 24 | -19.6% | 5.6% | ||
| Q1 24 | -17.9% | 0.6% |
| Q4 25 | 0.0% | 3.0% | ||
| Q3 25 | 0.1% | 3.8% | ||
| Q2 25 | 0.2% | 3.5% | ||
| Q1 25 | 0.2% | 2.2% | ||
| Q4 24 | 0.0% | 2.5% | ||
| Q3 24 | 0.1% | 3.7% | ||
| Q2 24 | 0.2% | 4.8% | ||
| Q1 24 | 0.2% | 3.7% |
| Q4 25 | -10.19× | 0.70× | ||
| Q3 25 | 2.95× | 0.35× | ||
| Q2 25 | 0.48× | 1.24× | ||
| Q1 25 | -0.63× | 2.07× | ||
| Q4 24 | -27.27× | 0.97× | ||
| Q3 24 | 1.46× | 1.81× | ||
| Q2 24 | -1.59× | 37.80× | ||
| Q1 24 | -1.32× | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
